Infections Associated With the Use of Alemtuzumab

The aim of this study is to propose infection prophylaxis from Asian multinational retrospective analysis of infectious complications in patients who were treated with alemtuzumab

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Patients Treated With Alemtuzumab Infections

Age range

15 year–90 year

Sex eligibility

All sexes

Study type

Observational

Primary location

Queen Mary Hospital, Hong Kong, China

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

Patients received alemtuzumab as a treatment for hematologic malignancy ex. non-Hodgkin lymphoma Acute myeloid leukemia Aplastic anemia

Exclusion criteria

Patients did not receive alemtuzumab

Treatment and study plan

Primary outcomes

Infectious event

Time frame: one year

Any infectious complication occurred within one year after the use of alemtuzumab

Sponsors and collaborators

Lead sponsor

Samsung Medical Center

Other

Collaborators

Asan Medical Center
Chonbuk National University
Chonnam National University
Chulalongkorn University
Dr Cipto Mangunkusumo General Hospital
Kyungpook National University Hospital
National Taiwan University Hospital
Queen Mary Hospital, Hong Kong
Soon Chun Hyang University
Yonsei University

Registry information

Official study title

Asian Multinational Retrospective Analysis for Infectious Complications in Patients Treated With Alemtuzumab

Important dates

Study start: 2009
Primary completion: 2012
Study completion: 2012
First posted: Mar 15, 2011
Registry last updated: May 24, 2012

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.

Completed